InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc.
815 West Hastings Street
Suite 310
Vancouver, BC V6C 1B4
Canada
604 669 7207
https://www.inmedpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 13
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Eric A. Adams B.S. Chem., M.I.B. | President, CEO & Director | 347.82k | N/D | 1963 |
| Mr. Michael Woudenberg P.Eng. | Chief Operating Officer | 287.54k | N/D | 1969 |
| Ms. Alexandra Diane-Janet Mancini M.Sc. | Senior Vice President of Clinical & Regulatory Affairs | 279.39k | N/D | 1953 |
| Dr. Sazzad Hossain M.Sc., Ph.D. | Co-Founder | 135.39k | N/D | 1958 |
| Ms. N. Netta Jagpal | CFO & Corporate Secretary | N/D | N/D | 1973 |
| Ms. Sarah Li CPA, CGA | VP of Accounting & Controller | N/D | N/D | N/D |
| Colin Clancy | Senior Director of Investor Relations | N/D | N/D | N/D |
| Mr. Jerry P. Griffin | Vice President of Sales & Marketing | N/D | N/D | N/D |
| Dr. Eric Chih-Hsien Hsu | Senior Vice President of Preclinical Research & Development | 253.46k | N/D | 1970 |
| Dr. Shane A. Johnson Ph.D. | Senior VP & GM of BayMedica | N/D | N/D | N/D |
Descripción
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de InMed Pharmaceuticals Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
